James Sarrett, MD
Family Medicine · Texarkana, TXNPI 1669467056
Payments from drug & device makers
Across 353 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$860
- Abbott$441
- Novo Nordisk$439
- Amgen$353
- Lilly USA, LLC$346
- Sanofi-aventis U.S. LLC$281
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,042100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $860 |
| Abbott | 30 | $441 |
| Novo Nordisk | 39 | $439 |
| Amgen | 25 | $353 |
| Lilly USA, LLC | 29 | $346 |
| Sanofi-aventis U.S. LLC | 21 | $281 |
| Bayer | 10 | $239 |
| GSK | 13 | $193 |
| Pfizer | 11 | $177 |
| Merck | 11 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $149 |
| Genentech USA, Inc. | 10 | $145 |
| AstraZeneca | 10 | $141 |
| Boehringer Ingelheim | 9 | $138 |
| Otsuka America Pharmaceutical, Inc. | 6 | $133 |
| Johnson & Johnson | 8 | $109 |
| Amarin Pharma, Inc. | 6 | $100 |
| Novartis | 4 | $86 |
| Astellas Pharma US Inc | 5 | $76 |
| Kowa Pharmaceuticals America, Inc. | 5 | $75 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Idorsia Pharmaceuticals US Inc | 3 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Mylan Specialty L.p. | 2 | $29 |
| Almatica Pharma LLC | 1 | $25 |
| Dexcom, Inc. | 1 | $25 |
| Nalpropion Pharmaceuticals LLC | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$115
How this compares
$5,042 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 137 | $160,896 |
| EliquisApixaban | 173 | $132,549 |
| JardianceEmpagliflozin | 139 | $109,246 |
| TrulicityDulaglutide | 28 | $35,820 |
| XareltoRivaroxaban | 35 | $35,386 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $29,283 |
| FarxigaDapagliflozin Propanediol | 32 | $23,312 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $22,875 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $20,648 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $17,849 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $17,132 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 27 | $15,954 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $13,256 |
| Repatha SyringeEvolocumab | 16 | $12,780 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $12,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $439 | $160,896137 claims |
| PfizerEliquis | $177 | $132,549173 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $138 | $120,020152 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $346 | $48,01440 claims |
| Johnson & JohnsonXarelto | $109 | $35,38635 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $141 | $33,69063 claims |
| MerckJanumet Xr, Januvia | $170 | $27,24042 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $281 | $25,16139 claims |
| GSKTrelegy Ellipta | $193 | $10,24316 claims |
| Esperion Therapeutics, Inc.Nexletol | $11 | $4,70412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Texarkana
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.